Notably, tRCC exhibit a high degree of morphologic and clinical heterogeneity, at least in part due to varying TFE3 fusion partners2, and their molecular landscape has only been partially defined, prompting an urgent need to identify biomarkers and therapeutic targets. Here, TFE3 is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.